within Pharmacolibrary.Drugs.C_CardiovascularSystem.C10A_LipidModifyingAgentsPlain.C10AA05_Atorvastatin;

model Atorvastatin
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.14,
    Cl = 1.0416666666666666e-05,
    adminDuration = 600,
    adminMass = 10 / 1000000,
    adminCount = 1,
    Vd = 0.381,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.03333333333333333,
    Tlag = 10.200000000000001,
    Vdp = 0.588,
    k12 = 0.00014972222222222223,
    k21 = 0.00014972222222222223);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Atorvastatin</td></tr><tr><td>ATC code:</td><td>C10AA05</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>10</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>381</td><td>L</td></tr>
    <tr><td>clearance:</td><td>625</td><td>mL/min</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Atorvastatin is a lipid-lowering medication (statin) used to prevent cardiovascular disease and to treat abnormal lipid levels. It works by inhibiting HMG-CoA reductase, a key enzyme in cholesterol biosynthesis. Atorvastatin is approved and widely used for lowering high cholesterol and reducing risk of heart attacks and strokes.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters have been reported for healthy adult volunteers after single 10 mg oral dose of atorvastatin.</p><h4>References</h4><ol><li><p>Tsamandouras, N, et al., &amp; Aarons, L (2017). Modelling of atorvastatin pharmacokinetics and the identification of the effect of a BCRP polymorphism in the Japanese population. <i>Pharmacogenetics and genomics</i> 27(1) 27–38. DOI:<a href=\"https://doi.org/10.1097/FPC.0000000000000252\">10.1097/FPC.0000000000000252</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27787353/\">https://pubmed.ncbi.nlm.nih.gov/27787353</a></p></li><li><p>Knebel, W, et al., &amp; Gandelman, K (2013). Population pharmacokinetics of atorvastatin and its active metabolites in children and adolescents with heterozygous familial hypercholesterolemia: selective use of informative prior distributions from adults. <i>Journal of clinical pharmacology</i> 53(5) 505–516. DOI:<a href=\"https://doi.org/10.1002/jcph.66\">10.1002/jcph.66</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23381936/\">https://pubmed.ncbi.nlm.nih.gov/23381936</a></p></li><li><p>Narwal, R, et al., &amp; Rosenbaum, SE (2010). Development of a population pharmacokinetic model for atorvastatin acid and its lactone metabolite. <i>Clinical pharmacokinetics</i> 49(10) 693–702. DOI:<a href=\"https://doi.org/10.2165/11535980-000000000-00000\">10.2165/11535980-000000000-00000</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/20818835/\">https://pubmed.ncbi.nlm.nih.gov/20818835</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.C.C10AA05 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Atorvastatin;
